Cargando…
Dronedarone in patients with congestive heart failure: insights from ATHENA
AIMS: Dronedarone is a new multichannel blocking antiarrhythmic drug for treatment of atrial fibrillation (AF). In patients with recently decompensated congestive heart failure (CHF) and depressed LV function, the drug was associated with excess mortality compared with a placebo group. The present s...
Autores principales: | Hohnloser, Stefan H., Crijns, Harry J.G.M., van Eickels, Martin, Gaudin, Christophe, Page, Richard L., Torp-Pedersen, Christian, Connolly, Stuart J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2903712/ https://www.ncbi.nlm.nih.gov/pubmed/20436046 http://dx.doi.org/10.1093/eurheartj/ehq113 |
Ejemplares similares
-
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study
por: Torp-Pedersen, Christian, et al.
Publicado: (2011) -
Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial
por: Pisters, Ron, et al.
Publicado: (2014) -
Efficacy and safety of dronedarone by atrial fibrillation history duration: Insights from the ATHENA study
por: Blomström‐Lundqvist, Carina, et al.
Publicado: (2020) -
Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022) -
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study
por: Vamos, Mate, et al.
Publicado: (2019)